Crown Bioscience is extending its existing portfolio of humanized drug target models (HuGEMM™) to its San Diego facility. This service offering expansion to the San Diego site will begin with humanized PD-1, PD-L1, CTLA-4, OX40, CD137, PD-1/PD-L1, and PD-1/CTLA-4 targets. Additional HuGEMM™ models will follow later this year to help advance development of immuno-oncology (I/O) drugs. The expansion of this novel translational platform to CrownBio’s San Diego laboratory makes it more...